(IMRX), Novavax (NVAX), (PYPD), Vertex Pharmaceuticals (VRTX) – Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
[ad_1] The U.S. Food and Drug Administration (FDA) has approved expanded use of Vertex’s VRTX lead asset ORKAMBI (lumacaftor/ivacaftor) to include children with cystic fibrosis (CF) ages 12 to <24…